PART I Item 1. Bus iness. Overview We are a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. We have a diverse portfolio of product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. We were founded in April 2016 and are led by a manage...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001193125-26-097558 | EDGAR | 95K words |
| 2025-04-15 | 2024-12-31 | 0000950170-25-053945 | EDGAR | 94K words |
| 2024-03-18 | 2023-12-31 | 0000950170-24-032819 | EDGAR | 100K words |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008456 | EDGAR | 99K words |
| 2022-03-14 | 2021-12-31 | 0000950170-22-003582 | EDGAR | — |
| 2021-03-22 | 2020-12-31 | 0001564590-21-014593 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-345876 | EDGAR | 65K words |
| 2025-11-10 | 2025-09-30 | 0001193125-25-274234 | EDGAR | 65K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108888 | EDGAR | 66K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064463 | EDGAR | 64K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124479 | EDGAR | 66K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095461 | EDGAR | 66K words |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058657 | EDGAR | 62K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062997 | EDGAR | 66K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042439 | EDGAR | 66K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021984 | EDGAR | 65K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024531 | EDGAR | 66K words |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016486 | EDGAR | 68K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001193125-26-345874 | EDGAR | 3K words |
| 2026-07-27 | 0001193125-26-316928 | EDGAR | 1K words |
| 2026-03-20 | 0001193125-26-117888 | EDGAR | 2K words |
| 2026-03-09 | 0001193125-26-097561 | EDGAR | 2K words |
| 2026-02-05 | 0001193125-26-039399 | EDGAR | 2K words |
| 2026-01-08 | 0001193125-26-007038 | EDGAR | 1K words |
| 2025-12-15 | 0001193125-25-318488 | EDGAR | 1K words |
| 2025-12-12 | 0001193125-25-317532 | EDGAR | 1K words |
| 2025-11-10 | 0001193125-25-274216 | EDGAR | 2K words |
| 2025-10-17 | 0001193125-25-242488 | EDGAR | 1K words |
97 total filings indexed. 69 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001683553 |
| Ticker | SPRB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.sprucebiosciences.com |
| Listed | 2020-10-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SPRB (~200 tokens, structured JSON with cryptographic provenance)